Effect of very low LDL-cholesterol on cortisol synthesis

Journal of Endocrinological Investigation

Volumn 31, Issue 12, 2008, Pages 1075-1078

  Sezer, Kerem ^a   Emral, R ^b   Corapcioglu, D ^b   Gen, R ^a   Akbay, E ^a  

^a MERSIN UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Cortisol; Low LDL cholesterol; Statin; Steroid

Indexed keywords

ATORVASTATIN; CORTICOTROPIN; HYDROCORTISONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADRENAL FUNCTION; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN TEST; DRUG TOLERABILITY; FEMALE; HORMONE RESPONSE; HORMONE SYNTHESIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; MALE; PROVOCATION TEST;

EID: 63249100011     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345655     Document Type: Article

References (38)

1. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335: 1001-9.
2. Randomized trial of cholesterol lowering in 4444 patients with conary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-9.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360: 7-22.
4. Rosenson S. Clinical trials of cholesterol lowering in patients with coronary heart disease. In: Basow DS ed. UpToDate. Waltham, MA: UpToDate, 2006.
5. Wilt TJ, Bloomfield HE, Macdonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004, 164: 1427-36.
6. Ryden L, Standl E, Bartnik M, et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28: 88-36.
7. Böhm M, Herrmann W, Wassmann S, Laufs U, Nickenig G. Does statin therapy influence steroid hormone synthesis? Z Kardiol 2004, 93: 43-8.
8. Illingworth DR, Kenny TA, Orwoll ES. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab 1982, 54: 27-33.
9. Illingworth DR, Lees AM, Lees RS. Adrenal cortical function in homozygous familial hypercholesterolemia. Metabolism 1983, 32: 1045-52.
10. Illingworth DR, Kenny TA, Connor WE, Orwoll ES. Corticosteroid production in abetalipoproteinemia: evidence for an impaired response ACTH. J Lab Clin Med 1982, 100: 115-26.
11. Illingworth DR, Alam NA, Lindsey S. Adrenocortical response to adrenocorticotropin in heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab 1984, 58: 206-11.
12. Illingworth DR, Orwoll ES, Connor WE. Impaired cortisol secretion in abetalipoproteinemia. J Clin Endocrinol Metab 1980, 50: 977-9.
13. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317: 1237-45.
14. Dickstein G, Spigel D, Arad E, Shechner C. One microgram is the lowest ACTH dose to cause a maximal cortisol response. There is no diurnal variation of cortisol response to submaximal ACTH stimulation. Eur J Endocrinol 1997, 137: 172-5.
15. Türkalp I, Cil Z, Ozkazanc D. Analytical performance of a direct assay for LDL-cholesterol: a comparative assessment versus Friedewald's formula. Anadolu Kardiyol Derg 2005, 5: 13-7.
16. Faust JR, Goldstein JL, Brown MS. Receptor-mediated uptake of low density lipoprotein and utilization of its cholesterol for steroid synthesis in cultured mouse adrenal cells. J Biol Chem 1977, 252: 4861-71.
17. Kovanen PT, Basu SK, Goldstein JL, Brown MS. Low density lipoprotein receptors in bovine adrenal cortex. II. Low density lipoprotein binding to membranes prepared from fresh tissue. Endocrinology 1979, 104: 610-6.
18. Gwynne JT, Hess B. The role of high density lipoproteins in rat adrenal cholesterol metabolism and steroidogenesis. J Biol Chem 1980, 255: 10875-83.
19. Gwynne JT, Mahaffee D, Brewer HB Jr, Ney RL. Adrenal cholesterol uptake from plasma lipoproteins: regulation by corticotropin. Proc Natl Acad Sci U S A 1976, 73: 4329-33.
20. Gwynne JT, Strauss JF, 3rd. The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands. Endocr Rev 1982, 3: 299-329.
21. Azhar S, Tsai L, Medicherla S, Azhar S, Tsai L, Medicheria S. Human granulosa cells use high density lipoprotein cholesterol for steroidogenesis. J Clin Endocrinol Metab 1998, 83: 983-91.
22. Borkowski AJ, Levin S, Delcroix C, Mahler A, Verhas V. Blood cholesterol and hydrocortisone production in man: quantitative aspects of the utilization of circulating cholesterol by the adrenals at rest and under adrenocorticotropin stimulation. J Clin Invest 1967, 46: 797-811.
23. Liang F, Kapoun AM, Lam A, et al. B-Type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells. Endocrinology 2007, 148: 3722-9.
24. Toth IE. Lipoprotein receptors and steroidogenesis in adrenocortical cells. J Steroid Biochem Mol Biol 1992, 43: 395-402.
25. Yaguchi H, Tsutsumi K, Shimono K, Omura M, Sasano H, Nishikawa T. Involwnent of high density lipoprotein as substrate cholesterol for steroidogenesis by bovine adrenal fasciculo-reticularis cells. Life Sci 1998, 62: 1387-95.
26. McNamara BC, Boyd GS. The role of lysine-rich proteins in the acute steroidogenic response of rat adrenal cells to ACTH. Biochem Biophys Res Commun 1984, 118: 400-4.
27. Laue L, Hoeg JM, Barnes K, Loriaux DI, Chrousos GP. The effect of mevinolin steroidogenesis in patients with defects in the low. density lipoprotein receptor pathway. J Clin Endocrinol Metab 1987, 64: 531-5.
28. Takeda Y, Miyamori I, Karayalçin U, Takeda R. Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on corticosteroid metabolism in patients with heterozygous familial hypercholesterolemia. Horm Res 1991, 36: 75-7.
29. Azzarito C, Boiardi L, Vergoni W, Zini M, Portioli I. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res 1996, 28: 193-8.
30. Farnsworth WH, Hoeg JM, Maher M, Brittain EH, Sherins RJ, Brewer HB Jr. Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin. J Clin Endocrinol Metab 1987, 65: 546-50.
31. Santini SA, Carrozza C, Lulli P, Zuppi C, Carlotonolo G, Musumeci S. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. J Atheroscler Thromb 2003, 10: 160-4.
32. Travia D, Tosi F, Negri C, Faccini G, Moghetti P, Muggeo M. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrinol Metab 1995, 80: 836-40.
33. Yamaguchi K, Nakamura N, Uzawa H. Blocking 3-hydroxy-3-methyl-glutaryl coenzyme A reductase with ML-236B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia. J Clin Endocrinol Metab 1984, 58: 786-9.
34. Bernini GP, Arqenio GF, Gasperi M, Vivaldi M S, Franchi F, Salvetti A. Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients. J Endocrinol Invest 1994, 17: 227-33.
35. Bernini GP, Brogi G, Argenio G F, Moretti A, Salvetti A. Effects of long-term pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients. J Endocrinol Invest 1998, 21: 310-7.
36. Mol MJ, Stalenhoef AF. Adrenocortical function in patients on simvastatin. Lancet 1990, 335: 412-3.
37. Jay RH, Sturley RH, Stirling C, et al. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol 1991, 32: 417-22.
38. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996, 34: 51-61.